CM
TEVA icon

CastleKnight Management’s Teva Pharmaceuticals TEVA Stock Holding History

CastleKnight Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,000
Closed -$606K – 480
2025
Q3 		$606K Buy
+30,000
New +$527K 0.01% 370
2024
Q3 		– Sell
-60,000
Closed -$975K – 404
2024
Q2 		$975K Sell
60,000
-60,000
-50% -$924K 0.05% 218
2024
Q1 		$1.69M Buy
+120,000
New +$1.51M 0.1% 143

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CastleKnight Management's TEVA Position: Q1 2026 in Review

CastleKnight Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 245,200 shares — an estimated $7.65M sold.

CastleKnight Management first reported a position in TEVA in Q4 2023 and held it in 9 quarters. The position peaked at $12.7M in Q3 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • CastleKnight Management reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • CastleKnight Management sold 245,200 Teva Pharmaceuticals shares in Q1 2026, an estimated $7.65M.
  • CastleKnight Management first reported a position in Teva Pharmaceuticals in Q4 2023 and held it in 9 quarters.
  • CastleKnight Management's Teva Pharmaceuticals position peaked at $12.7M in Q3 2025.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on CastleKnight Management's 13F filing for Q1 2026, filed 15 May 2026.